Literature DB >> 23669290

XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells.

Bing Z Carter1, Duncan H Mak, Zhiqiang Wang, Wencai Ma, Po Yee Mak, Michael Andreeff, R Eric Davis.   

Abstract

To further understand the role of XIAP in acute myeloid leukemia (AML), we suppressed XIAP expression by antisense oligonucleotides and determined the effect on gene expression profiles and biological pathways. XIAP inhibition upregulated expression of proteasome genes in a manner similar to the proteasome inhibitor bortezomib or MG132; decreased 20S proteasome activity, an effect which was diminished in the presence of a pan-caspase inhibitor; and increased IκBα, Mcl-1, and HSP70 in AML cells. In addition to multiple functions already described, XIAP contributes to increased proteasome activity in AML cells, and the antitumor effect of XIAP inhibition may be mediated in part through caspase-dependent proteasome inhibition.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23669290      PMCID: PMC3700666          DOI: 10.1016/j.leukres.2013.04.018

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  27 in total

1.  Assessing clusters and motifs from gene expression data.

Authors:  L M Jakt; L Cao; K S Cheah; D K Smith
Journal:  Genome Res       Date:  2001-01       Impact factor: 9.043

2.  Structural basis of caspase-7 inhibition by XIAP.

Authors:  J Chai; E Shiozaki; S M Srinivasula; Q Wu; P Datta; E S Alnemri; Y Shi; P Dataa
Journal:  Cell       Date:  2001-03-09       Impact factor: 41.582

3.  Structural basis for the inhibition of caspase-3 by XIAP.

Authors:  S J Riedl; M Renatus; R Schwarzenbacher; Q Zhou; C Sun; S W Fesik; R C Liddington; G S Salvesen
Journal:  Cell       Date:  2001-03-09       Impact factor: 41.582

4.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

5.  X-linked inhibitor of apoptosis protein functions as a cofactor in transforming growth factor-beta signaling.

Authors:  S Birkey Reffey; J U Wurthner; W T Parks; A B Roberts; C S Duckett
Journal:  J Biol Chem       Date:  2001-05-16       Impact factor: 5.157

6.  Activation of specific apoptotic caspases with an engineered small-molecule-activated protease.

Authors:  Daniel C Gray; Sami Mahrus; James A Wells
Journal:  Cell       Date:  2010-08-20       Impact factor: 41.582

7.  XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML.

Authors:  Bing Z Carter; Duncan H Mak; Stephen J Morris; Gautam Borthakur; Elihu Estey; Anna L Byrd; Marina Konopleva; Hagop Kantarjian; Michael Andreeff
Journal:  Apoptosis       Date:  2011-01       Impact factor: 4.677

8.  Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells.

Authors:  M L Guzman; S J Neering; D Upchurch; B Grimes; D S Howard; D A Rizzieri; S M Luger; C T Jordan
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

9.  Effect of long-term storage in TRIzol on microarray-based gene expression profiling.

Authors:  Wencai Ma; Michael Wang; Zhi-Qiang Wang; Luhong Sun; David Graber; Jairo Matthews; Richard Champlin; Qing Yi; Robert Z Orlowski; Larry W Kwak; Donna M Weber; Sheeba K Thomas; Jatin Shah; Steven Kornblau; Richard E Davis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08-30       Impact factor: 4.254

10.  Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells.

Authors:  Senthil K Radhakrishnan; Candy S Lee; Patrick Young; Anne Beskow; Jefferson Y Chan; Raymond J Deshaies
Journal:  Mol Cell       Date:  2010-04-09       Impact factor: 17.970

View more
  6 in total

1.  Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia.

Authors:  Xuejie Jiang; Po Yee Mak; Hong Mu; Wenjing Tao; Duncan H Mak; Steven Kornblau; Qi Zhang; Peter Ruvolo; Jared K Burks; Weiguo Zhang; Teresa McQueen; Rongqing Pan; Hongsheng Zhou; Marina Konopleva; Jorge Cortes; Qifa Liu; Michael Andreeff; Bing Z Carter
Journal:  Clin Cancer Res       Date:  2018-02-20       Impact factor: 12.531

Review 2.  Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities.

Authors:  S Fulda
Journal:  Leukemia       Date:  2014-02-03       Impact factor: 11.528

3.  The Marine Dinoflagellate Alexandrium andersoni Induces Cell Death in Lung and Colorectal Tumor Cell Lines.

Authors:  Clementina Sansone; Genoveffa Nuzzo; Christian Galasso; Raffaella Casotti; Angelo Fontana; Giovanna Romano; Adrianna Ianora
Journal:  Mar Biotechnol (NY)       Date:  2018-04-20       Impact factor: 3.619

4.  Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.

Authors:  Bing Z Carter; Po Yee Mak; Hong Mu; Hongsheng Zhou; Duncan H Mak; Wendy Schober; Joel D Leverson; Bin Zhang; Ravi Bhatia; Xuelin Huang; Jorge Cortes; Hagop Kantarjian; Marina Konopleva; Michael Andreeff
Journal:  Sci Transl Med       Date:  2016-09-07       Impact factor: 17.956

5.  Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.

Authors:  Bing Z Carter; Po Yee Mak; Duncan H Mak; Vivian R Ruvolo; Wendy Schober; Teresa McQueen; Jorge Cortes; Hagop M Kantarjian; Richard E Champlin; Marina Konopleva; Michael Andreeff
Journal:  Oncotarget       Date:  2015-10-13

6.  Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network.

Authors:  Bing Z Carter; Po Yee Mak; Ye Chen; Duncan H Mak; Hong Mu; Rodrigo Jacamo; Vivian Ruvolo; Stefan T Arold; John E Ladbury; Jared K Burks; Steven Kornblau; Michael Andreeff
Journal:  Oncotarget       Date:  2016-04-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.